These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 37629716)

  • 1. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 2. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
    Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
    Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
    Zhu C; Zhang C; Wang S; Xun Z; Zhang D; Lan Z; Zhang L; Chao J; Liang Y; Pu Z; Ning C; Sang X; Yang X; Wang H; Jiang X; Zhao H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.
    Li L; Ye J
    Medicine (Baltimore); 2020 Sep; 99(37):e21788. PubMed ID: 32925716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and immunotherapy of renal cell carcinoma.
    Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
    Li Q; Han J; Yang Y; Chen Y
    Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
    Tao S; Liang S; Zeng T; Yin D
    Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.